Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia

Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison

(2018) Saeed Taheri et al.   JOURNAL OF MEDICAL ECONOMICS

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

(2017) GJ Melendez-Torres et al.   HEALTH TECHNOLOGY ASSESSMENT

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

(2016) Hasnat Ahmad et al.   Multiple Sclerosis Journal

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

(2016) Hasnat Ahmad et al.   Multiple Sclerosis Journal

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

(2016) Luis Hernandez et al.   JOURNAL OF MEDICAL ECONOMICS

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

(2016) Duygu Bozkaya et al.   JOURNAL OF MEDICAL ECONOMICS

Governments Need Better Guidance to Maximise Value for Money: The Case of Australia’s Pharmaceutical Benefits Advisory Committee

(2016) Drew Carter et al.   Applied Health Economics and Health Policy

Revised diagnostic criteria of multiple sclerosis

(2014) Ron Milo et al.   AUTOIMMUNITY REVIEWS

Economic costs associated with an MS relapse

(2014) K. O׳Connell et al.   Multiple Sclerosis and Related Disorders

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis

(2013) Sarah Thomas et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

The economic impact of multiple sclerosis in Australia in 2010

(2013) Andrew J Palmer et al.   Multiple Sclerosis Journal

Assessing possible selection bias in a national voluntary MS longitudinal study in Australia

(2013) Bruce V Taylor et al.   Multiple Sclerosis Journal

Mortality in patients with multiple sclerosis

(2013) A. Scalfari et al.   NEUROLOGY

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

(2013) Jonathan D. Campbell et al.   Multiple Sclerosis and Related Disorders

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

(2012) John P. Caloyeras et al.   CLINICAL THERAPEUTICS

Model Parameter Estimation and Uncertainty Analysis

(2012) Andrew H. Briggs et al.   MEDICAL DECISION MAKING

State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3

(2012) Uwe Siebert et al.   VALUE IN HEALTH

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

(2012) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

(2012) Soyon Lee et al.   JOURNAL OF MEDICAL ECONOMICS

Time Trade-Off Derived EQ-5D Weights for Australia

(2011) Rosalie Viney et al.   VALUE IN HEALTH

Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis

(2011) A.J. Palmer et al.   Primary Care Diabetes

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

(2009) Michael Drummond et al.   VALUE IN HEALTH